BNC KOREA, Inc.
Founded and listed on the KOSDAQ in 2016, BNC Korea is a biohealthcare company specializing in HA fillers, botulinum toxin, and dermo-cosmetics.
Price
Change
Market cap
Products & technology
- HA FillerHyaluronic acid-based dermal filler for volume and wrinkle improvement
- Botulinum toxin pharmaceuticalWrinkle improvement, muscle spasm, and hyperhidrosis treatment
- Collagen-based absorbable wound dressingWound dressing
- Anti-adhesion materialPost-surgical adhesion prevention
- I.stDerma-cosmetic brand (skin regeneration, whitening, wrinkle care)
Regulatory approvals
data.go.kr8 Korean MFDS drug approvals · 2012–2024 / 43 Korean MFDS device approvals · 2008–2022
- MFDS drugBIENOX Injection 200 unit(Clostridium Botulinum Toxin Type A)(for export)2024-11-28Drug · Prescription · Approval202402821
- MFDS drugBIENOX Injection(Clostridium Botulinum Toxin Type A)2024-03-21Drug · Prescription · Approval202400591
- MFDS drugMabenfomin Soft Capsule2023-02-28Drug · OTC · Notification202300719
- MFDS drugBNCDapa Tab.2023-01-31Drug · Prescription · Approval202300425
- MFDS drugTopcondor 600 Tab.2022-09-16Drug · OTC · Notification202203582
- MFDSGraft/prosthesis, biomaterial2022-06-02Product approval · Class 4제허 22-364 호
- MFDSGraft/prosthesis, biomaterial2022-01-28Product approval · Class 4제허 22-71 호
- MFDSGraft/prosthesis, biomaterial2021-09-29Product approval · Class 4제허 21-806 호
- MFDSGraft/prosthesis, biomaterial2021-08-06Product approval · Class 4제허 21-670 호
- MFDSDressing, fluid-impermeable film2021-01-27Product approval · Class 2제인 21-4056 호
- MFDSGraft/prosthesis, biomaterial2021-01-20Product approval · Class 4제허 21-48 호
- MFDSGraft/prosthesis, biomaterial2020-12-18Product approval · Class 4제허 20-1106 호
Show 39 more
- MFDSTissue supplement, collagen2020-09-01Product approval · Class 4제허 20-768 호
- MFDS drugBIENOX Injection(Clostridium Botulinum Toxin Type A)(for export only)2020-01-13Drug · Prescription · Approval202000204
- MFDSGraft/prosthesis, biomaterial2019-09-06Product approval · Class 4제허 19-579 호
- MFDSTissue supplement, collagen2019-07-18Product approval · Class 4제허 19-470 호
- MFDSGraft/prosthesis, biomaterial2019-04-17Product approval · Class 4제허 19-255 호
- MFDSGraft/prosthesis, biomaterial2019-04-17Product approval · Class 4제허 19-254 호
- MFDSGraft/prosthesis, biomaterial2018-10-10Product approval · Class 4제허 18-667 호
- MFDSGraft/prosthesis, biomaterial2018-07-11Product approval · Class 4제허 18-491 호
- MFDSGraft/prosthesis, biomaterial2018-05-23Product approval · Class 4제허 18-371 호
- MFDSGraft/prosthesis, biomaterial2018-02-09Product approval · Class 4제허 18-79 호
- MFDSGraft/prosthesis, biomaterial2017-12-20Product approval · Class 4제허 17-966 호
- MFDSDressing, fluid-impermeable film2017-12-18Product approval · Class 2제인 17-4973 호
- MFDSTissue supplement, collagen2017-07-24Product approval · Class 4제허 17-545 호
- MFDSGraft/prosthesis2017-05-15Product approval · Class 4제허 17-314 호
- MFDSGraft/prosthesis, biomaterial2017-04-18Product approval · Class 4제허 17-271 호
- MFDSGraft/prosthesis2017-04-14Product approval · Class 4제허 17-268 호
- MFDSInfusion pump, electrically-poweredRevoked2016-10-24Product approval · Class 2제인 16-4817 호
- MFDSDressing, secondardy treatment, high-absorbent, foam/ sheet/ liquid/powder2016-05-11Product approval · Class 3제허 16-352 호
- MFDSGraft/prosthesis, biomaterial2016-04-22Product approval · Class 4제허 16-310 호
- MFDSGraft/prosthesis, biomaterial2016-03-24Product approval · Class 4제허 16-219 호
- MFDSGraft/prosthesis, biomaterial2015-11-25Product approval · Class 4제허 15-1616 호
- MFDSGraft/prosthesis, biomaterial2015-08-19Product approval · Class 4제허 15-1317 호
- MFDSGraft/prosthesis, biomaterial2015-08-19Product approval · Class 4제허 15-1318 호
- MFDSGraft/prosthesis, biomaterial2015-08-17Product approval · Class 4제허 15-1313 호
- MFDSGraft/prosthesis, biomaterial2015-06-22Product approval · Class 4제허 15-988 호
- MFDSDressing, secondardy treatment, high-absorbent, foam/ sheet/ liquid/powder2015-06-11Product approval · Class 3제허 15-921 호
- MFDSDressing, secondardy treatment, high-absorbent, foam/ sheet/ liquid/powder2015-06-11Product approval · Class 3제허 15-922 호
- MFDSDressing, secondardy treatment, high-absorbent, foam/ sheet/ liquid/powder2015-06-11Product approval · Class 3제허 15-923 호
- MFDSDressing, secondardy treatment, high-absorbent, foam/ sheet/ liquid/powder2015-06-11Product approval · Class 3제허 15-924 호
- MFDSGraft/prosthesis, biomaterial2015-03-31Product approval · Class 4제허 15-452 호
- MFDSDressing, collagen, wound2015-02-13Product approval · Class 3제허 15-207 호
- MFDSGraft/prosthesis, biomaterial2013-11-04Product approval · Class 4제허 13-1868 호
- MFDS drugFlucazole Cap. 50mg2013-07-31Drug · Prescription · Approval201308613
- MFDSBandage, compressionRevoked2013-05-28Product approval · Class 1대구 제신 13-23 호
- MFDSDressing, adhesion barrier2013-05-08Product approval · Class 3제허 13-815 호
- MFDSDressing, adhesion barrier2012-10-17Product approval · Class 3제허 12-1313 호
- MFDS drugRinger Light Sol.2012-09-17Drug · Prescription · Notification201206825
- MFDSGraft/prosthesis, biomaterial2011-12-05Product approval · Class 4제허 11-1322 호
- MFDS탄력밴드Revoked2008-01-23Product approval · Class 1경인 제신 08-20 호
Clinical trials
data.go.kr1 MFDS clinical trial authorisations · 2022 (Bioequivalence 1)
- Bioequivalence비엔씨다파정10밀리그램(다파글리플로진프로판디올수화물)2022-03-28
2 trial sites
R&D and key agreements
Source: DART corporate disclosureBKP001 · 대사질환 · 초기기술습득단계 · Licensed to Chinese company E Corp for worldwide rights (excluding China, Russia, Mexico, Turkey, Pakistan), signed February 27, 2019, total contract value KRW 2.4 billion, 3% royalty on net sales.
BKP005 · 샘플대기단계 · Licensed to U.S. company N Corp for sales rights (Korea) and manufacturing rights (Asia); total contract value KRW 1.2 billion, 8% royalty on net sales, based on nano-formulation technology.
Antroquinonol(Hocena) · COVID-19 · 미국 FDA 임상2상 완료 · Licensed COVID-19 treatment Antroquinonol (brand name Hocena) from Taiwan's Golden Biotechnology Corporation for Korea, Brazil, Turkey, and Indonesia (contracted January 2021, amended November 2022); total contract value up to USD 15 million upon Phase 3 completion and approval, with a 12% royalty.
Companies approved for the same productsPharma & CDMO
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
Founded in 2003 and KOSDAQ-listed in 2021, BioPlus develops HA-based bio medical devices and biopharmaceuticals using its proprietary MDM Technology platform.
KOSDAQ-listed comprehensive healthcare and pharmaceutical company behind the gum treatment Insadol and the wound-care ointment Madecassol.
KOSDAQ-listed medical device maker producing disposable acupuncture needles, cupping cups, and hyaluronic acid dermal fillers.
Founded 2009, listed on KOSDAQ in 2019, JETEMA develops hyaluronic acid fillers, botulinum toxin biopharmaceuticals, and lifting threads.
KOSDAQ-listed medical device company producing PDRN pharmaceuticals, HA fillers, and Rejuran-branded cosmetics.
L&C BIO manufactures human tissue grafts across 11 tissue types, including the acellular dermal matrix MegaDerm, plus tissue-based medical devices.
KOSDAQ-listed aesthetics and CMO company behind the Elravie/Revolax hyaluronic-acid fillers and Leedstox botulinum toxin.
KOSDAQ-listed medical device company producing human tissue implants Bella Cell HD and SureFuse.
KOSPI-listed operating holding company of the Hanmi Pharm group, also running healthcare and pharmaceutical wholesale businesses.
Wonbiogen Co.,Ltd., established September 2018, listed on KOSDAQ in December 2018, manufactures wound dressings and moist wound dressings.
Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.
KOSDAQ-listed medical device company manufacturing synthetic bioresorbable suture yarn and dental root canal filling materials.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition